INR 629.4
(3.05%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.09 Billion INR | -30.65% |
2022 | 1.58 Billion INR | 5.86% |
2021 | 1.49 Billion INR | 24.27% |
2020 | 1.2 Billion INR | 3.18% |
2019 | 1.16 Billion INR | 12.75% |
2018 | 1.03 Billion INR | 7.7% |
2017 | 961.48 Million INR | 3.57% |
2016 | 928.33 Million INR | 3.92% |
2015 | 893.28 Million INR | 8.21% |
2014 | 825.53 Million INR | 25.69% |
2013 | 656.8 Million INR | 4.96% |
2012 | 625.75 Million INR | 6.32% |
2011 | 588.55 Million INR | 111.35% |
2010 | 278.46 Million INR | -31.98% |
2009 | 409.39 Million INR | 14.88% |
2008 | 356.35 Million INR | -0.29% |
2007 | 357.38 Million INR | 16.26% |
2006 | 307.38 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 223.2 Million INR | -35.55% |
2023 Q3 | 267.98 Million INR | -37.84% |
2023 Q1 | 314.85 Million INR | -16.15% |
2023 FY | 1.09 Billion INR | -30.65% |
2023 Q2 | 431.1 Million INR | 36.92% |
2023 Q4 | 346.3 Million INR | 29.23% |
2022 Q4 | 375.51 Million INR | -16.3% |
2022 Q1 | 337.03 Million INR | -8.14% |
2022 Q2 | 423.57 Million INR | 25.68% |
2022 FY | 1.58 Billion INR | 5.86% |
2022 Q3 | 448.64 Million INR | 5.92% |
2021 Q4 | 366.88 Million INR | -6.28% |
2021 FY | 1.49 Billion INR | 24.27% |
2021 Q1 | 307.76 Million INR | -23.1% |
2021 Q2 | 384.32 Million INR | 24.88% |
2021 Q3 | 391.44 Million INR | 1.85% |
2020 Q1 | 186.27 Million INR | -31.98% |
2020 Q4 | 400.19 Million INR | 16.55% |
2020 Q3 | 343.36 Million INR | 29.59% |
2020 Q2 | 264.95 Million INR | 42.24% |
2020 FY | 1.2 Billion INR | 3.18% |
2019 Q2 | 305.45 Million INR | 35.23% |
2019 Q4 | 273.84 Million INR | -24.42% |
2019 Q3 | 362.33 Million INR | 18.62% |
2019 Q1 | 225.88 Million INR | -15.02% |
2019 FY | 1.16 Billion INR | 12.75% |
2018 Q1 | 211.3 Million INR | -31.52% |
2018 FY | 1.03 Billion INR | 7.7% |
2018 Q4 | 265.8 Million INR | -14.39% |
2018 Q3 | 310.49 Million INR | 25.26% |
2018 Q2 | 247.87 Million INR | 17.3% |
2017 Q2 | 204.28 Million INR | 6.81% |
2017 FY | 961.48 Million INR | 3.57% |
2017 Q3 | 306.49 Million INR | 50.04% |
2017 Q4 | 308.58 Million INR | 0.68% |
2017 Q1 | 191.25 Million INR | -39.85% |
2016 Q3 | 267.45 Million INR | 6.47% |
2016 Q2 | 251.19 Million INR | 0.0% |
2016 FY | 928.33 Million INR | 3.92% |
2016 Q4 | 317.96 Million INR | 18.89% |
2015 FY | 893.28 Million INR | 8.21% |
2014 FY | 825.53 Million INR | 25.69% |
2013 FY | 656.8 Million INR | 4.96% |
2012 Q2 | 107.8 Million INR | 46.78% |
2012 Q3 | 169.42 Million INR | 57.16% |
2012 Q4 | 234.83 Million INR | 38.61% |
2012 FY | 625.75 Million INR | 6.32% |
2012 Q1 | 73.44 Million INR | 0.0% |
2011 FY | 588.55 Million INR | 111.35% |
2010 FY | 278.46 Million INR | -31.98% |
2009 FY | 409.39 Million INR | 14.88% |
2008 FY | 356.35 Million INR | -0.29% |
2007 FY | 357.38 Million INR | 16.26% |
2006 FY | 307.38 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 93.075% |
Aurobindo Pharma Limited | 39.23 Billion INR | 97.199% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 90.559% |
Granules India Limited | 7.18 Billion INR | 84.699% |
Indoco Remedies Limited | 4.74 Billion INR | 76.857% |
Achyut Healthcare Limited | 1.6 Million INR | -68202.548% |
Ajanta Pharma Limited | 30.46 Billion INR | 96.392% |
Alkem Laboratories Limited | 32.83 Billion INR | 96.653% |
Alpa Laboratories Limited | 156.14 Million INR | -603.816% |
Brooks Laboratories Limited | 51.18 Million INR | -2047.3% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 57.738% |
Bajaj HealthCare Limited | 985.34 Million INR | -11.533% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 22.564% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.854% |
Eris Lifesciences Limited | 4.94 Billion INR | 77.767% |
FDC Limited | 5.34 Billion INR | 79.453% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.373% |
Gufic Biosciences Limited | 1.07 Billion INR | -1.974% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 48.263% |
Ipca Laboratories Limited | 13.91 Billion INR | 92.102% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -42.096% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2281.03% |
Lasa Supergenerics Limited | 291.17 Million INR | -277.433% |
Laurus Labs Limited | 3.01 Billion INR | 63.498% |
Lupin Limited | 95.67 Billion INR | 98.851% |
Mankind Pharma Limited | 23.15 Billion INR | 95.253% |
Medicamen Biotech Limited | 335.16 Million INR | -227.893% |
Medico Remedies Limited | 161.84 Million INR | -579.042% |
Megasoft Limited | 49.52 Million INR | -2118.923% |
NATCO Pharma Limited | 10.05 Billion INR | 89.073% |
Piramal Pharma Limited | 19.91 Billion INR | 94.481% |
RPG Life Sciences Limited | 1.63 Billion INR | 32.804% |
Sigachi Industries Limited | 579.88 Million INR | -89.518% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.287% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 21.657% |
Syncom Formulations (India) Limited | 942.39 Million INR | -16.616% |
Unichem Laboratories Limited | 6.72 Billion INR | 83.66% |
Wanbury Limited | 1.16 Billion INR | 5.335% |
Windlas Biotech Limited | 1 Billion INR | -9.188% |
ZIM Laboratories Limited | 1.01 Billion INR | -8.482% |
Zydus Lifesciences Limited | 43.17 Billion INR | 97.455% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 64.281% |
Divi's Laboratories Limited | 14.17 Billion INR | 92.244% |
Hester Biosciences Limited | 908.84 Million INR | -20.922% |
Procter & Gamble Health Limited | 2.99 Billion INR | 63.311% |
Bal Pharma Limited | 389.89 Million INR | -181.871% |
Strides Pharma Science Limited | 9.16 Billion INR | 88.005% |
Venus Remedies Limited | 1.91 Billion INR | 42.65% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 64.254% |
Nectar Lifesciences Limited | 625.55 Million INR | -75.683% |
Shilpa Medicare Limited | 2.18 Billion INR | 49.601% |
Aarti Drugs Limited | 1.16 Billion INR | 5.867% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -0.017% |
Suven Life Sciences Limited | 109.75 Million INR | -901.356% |
Ind-Swift Limited | 946.56 Million INR | -16.103% |
Valiant Laboratories Limited | 36.28 Million INR | -2928.433% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 86.943% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 76.003% |
Themis Medicare Limited | 782.85 Million INR | -40.382% |
Hikal Limited | 2.48 Billion INR | 55.799% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 94.87% |
Sequent Scientific Limited | 2.9 Billion INR | 62.127% |
Novartis India Limited | 470.1 Million INR | -133.777% |
Wockhardt Limited | 6.4 Billion INR | 82.828% |
Jubilant Pharmova Limited | 14.45 Billion INR | 92.397% |
Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -6679.817% |
Neuland Laboratories Limited | 2.92 Billion INR | 62.489% |
Morepen Laboratories Limited | 1.98 Billion INR | 44.704% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -166.468% |
Mangalam Drugs & Organics Limited | 676.14 Million INR | -62.537% |